Inovio Pharmaceuticals is engaged in the development of synthetic vaccines, with a focus on cancers and infectious diseases. The company’s SynCon technology enables the design of universal vaccines capable of providing cross-protection against pathogens, such as influenza and human immunodeficiency virus (HIV). INO’s clinical programs include cervical dysplasia (therapeutic), avian influenza (preventive), prostate cancer (therapeutic), leukemia (therapeutic), hepatitis C virus (HCV), and HIV vaccines. For more information, visit the company’s Web site at: www.inovio.com

Noble Financial Capital Markets, an equity research driven, full-service, investment banking boutique, is hosting its ninth annual equity conference at The Hard Rock Hotel in Ft. Lauderdale, FL. Attended by institutional investors from across North America, the event features 135 public company executive teams with an emphasis on healthcare, technology, defense, and new-media / entertainment sectors.

Let us hear your thoughts below: